NCT06911944: An ongoing trial by Michael Rafii, MD, PhD
This trial is ongoing. It must report results 4 years from now.
Full data
| Full entry on ClinicalTrials.gov | NCT06911944 |
|---|---|
| Title | A Randomized, Double-Blind, Placebo-Controlled, Phase 4 Dose-Escalation Study Evaluating the Safety, Tolerability, and Efficacy of Donanemab in Adults With Down Syndrome |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Aug. 1, 2026 |
| Completion date | Dec. 31, 2028 |
| Required reporting date | Dec. 31, 2029, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | None |